Waters Shareholders' Decisive Vote Endorses BD Biosciences Integration Deal - Completion Expected This Month

2026-02-06 09:09:16

Abstract generation in progress

In a strong show of investor support, Waters Corporation shareholders have overwhelmingly backed the proposed combination with Becton, Dickinson and Company’s Biosciences & Diagnostic Solutions business. The approval came Tuesday at a Special Meeting of Shareholders, where approximately 99 percent of present and proxy votes endorsed the stock issuance plan. This decisive shareholder endorsement demonstrates investor confidence in the strategic transaction, which is set to close on February 9, 2026 - just days away.

CEO Udit Batra commented on the milestone, stating: “We appreciate the continued support of our shareholders as we move closer to completing this transaction. We look forward to creating meaningful value for patients, customers, employees, and shareholders alike.” The overwhelming vote count, representing roughly 99 percent approval, reflects the investment community’s belief in the merger’s strategic merit and long-term potential.

Market Sentiment Reflects Positive Reception

The market’s response to the shareholder approval has been measured, with both companies’ stocks showing minimal movement. Waters (WAT) is currently trading at $390.54, down 0.09 percent from previous levels, while Becton Dickinson (BDX) is valued at $203.36, down just 0.02 percent on the New York Stock Exchange. The stability in both stock prices alongside the overwhelming shareholder vote suggests investors view the combination as a value-accretive transaction.

Final Stretch: Transaction Set To Close Within Days

With shareholder approval now secured and the completion date of February 9, 2026 imminent, Waters and BD are in the final stages of bringing this integration to fruition. The combination will integrate BD’s specialized biosciences and diagnostic solutions capabilities with Waters’ established scientific instruments and lab software platform, creating a more comprehensive life sciences solutions provider. This strategic merger represents a significant consolidation in the life sciences and diagnostics sector, positioning the combined entity to better serve customers across pharmaceutical, biotech, and diagnostic industries.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.